The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: A double-blind, randomized, placebo-controlled trial

Schizophrenia Research

Volumn 160, Issue 1-3, 2014, Pages 180-185

  Tek, Cenk ^a   Palmese, Laura B ^a   Krystal, Andrew D ^b   Srihari, Vinod H ^a   DeGeorge, Pamela C ^c   Reutenauer, Erin L ^a   Guloksuz, Sinan ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cognition; Eszopiclone; Insomnia; Schizophrenia; Sleep; Working memory

Indexed keywords

ESZOPICLONE; PLACEBO; AZABICYCLO DERIVATIVE; HYPNOTIC SEDATIVE AGENT; PIPERAZINE DERIVATIVE;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INSOMNIA; INSOMNIA SEVERITY INDEX; MALE; MENTAL DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SLEEP; SLEEP QUALITY; TREATMENT WITHDRAWAL; WORKING MEMORY; XEROSTOMIA; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MEDICAL RECORD; MIDDLE AGED; PATIENT DROPOUTS; PSYCHOLOGY; PSYCHOSIS; SINGLE BLIND PROCEDURE; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

AZABICYCLO COMPOUNDS; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MEDICAL RECORDS; MIDDLE AGED; PATIENT DROPOUTS; PIPERAZINES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SINGLE-BLIND METHOD; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 84928266475     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.10.002     Document Type: Article

References (42)

1. Ancoli-Israel S., Krystal A.D., McCall W.V., Schaefer K., Wilson A., Claus R., Rubens R., Roth T. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep 2010, 33(2):225-234.
2. Bastien C.H., Vallieres A., Morin C.M. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001, 2(4):297-307.
3. Buckley P.F., Correll C.U. Strategies for dosing and switching antipsychotics for optimal clinical management. J. Clin. Psychiatry 2008, 69(Suppl. 1):4-17.
4. Carnahan R.M., Lund B.C., Perry P.J., Chrischilles E.A. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr. Scand. 2006, 113(2):135-141.
5. Carskadon M.A., Dement W.C., Mitler M.M., Guilleminault C., Zarcone V.P., Spiegel R. Self-reports versus sleep laboratory findings in 122 drug-free subjects with complaints of chronic insomnia. Am. J. Psychiatry 1976, 133(12):1382-1388.
6. Chemerinski E., Ho B.C., Flaum M., Arndt S., Fleming F., Andreasen N.C. Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Compr. Psychiatry 2002, 43(5):393-396.
7. Chouinard S., Poulin J., Stip E., Godbout R. Sleep in untreated patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2004, 30(4):957-967.
8. Goder R., Boigs M., Braun S., Friege L., Fritzer G., Aldenhoff J.B., Hinze-Selch D. Impairment of visuospatial memory is associated with decreased slow wave sleep in schizophrenia. J. Psychiatr. Res. 2004, 38(6):591-599.
9. Goldman M., Tandon R., DeQuardo J.R., Taylor S.F., Goodson J., McGrath M. Biological predictors of 1-year outcome in schizophrenia in males and females. Schizophr. Res. 1996, 21(2):65-73.
10. Hamera E., Brown C., Goetz J. Objective and subjective sleep disturbances in individuals with psychiatric disabilities. Issues Ment. Health Nurs. 2013, 34(2):110-116.
11. Hermes E.D., Sernyak M., Rosenheck R. Use of second-generation antipsychotic agents for sleep and sedation: a provider survey. Sleep 2013, 36(4):597-600.
12. Hofstetter J.R., Lysaker P.H., Mayeda A.R. Quality of sleep in patients with schizophrenia is associated with quality of life and coping. BMC Psychiatry 2005, 5:13.
13. Kajimura N., Kato M., Okuma T., Onuma T. Effects of zopiclone on sleep and symptoms in schizophrenia: comparison with benzodiazepine hypnotics. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1994, 18(3):477-490.
14. Kajimura N., Kato M., Okuma T., Sekimoto M., Watanabe T., Takahashi K. A quantitative sleep-EEG study on the effects of benzodiazepine and zopiclone in schizophrenic patients. Schizophr. Res. 1995, 15(3):303-312.
15. Kato M., Kajimura N., Okuma T., Sekimoto M., Watanabe T., Yamadera H., Takahashi K. Association between delta waves during sleep and negative symptoms in schizophrenia. Pharmaco-eeg studies by using structurally different hypnotics. Neuropsychobiology 1999, 39(3):165-172.
16. Keshavan M.S., Diwadkar V.A., Montrose D.M., Stanley J.A., Pettegrew J.W. Premorbid characterization in schizophrenia: the Pittsburgh High Risk Study. World Psychiatry 2004, 3(3):163-168.
17. Krystal A., Fava M., Rubens R., Wessel T., Caron J., Wilson P., Roth T., McCall W.V. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J. Clin. Sleep Med. 2007, 3(1):48-55.
18. Krystal A.D., Thakur M., Roth T. Sleep disturbance in psychiatric disorders: effects on function and quality of life in mood disorders, alcoholism, and schizophrenia. Ann. Clin. Psychiatry 2008, 20(1):39-46.
19. Krystal A.D., McCall W.V., Fava M., Joffe H., Soares C.N., Huang H., Grinell T., Zummo J., Spalding W., Marshall R. Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity. Prim. Care Companion CNS Disord. 2012, 14(4).
20. Lauer C.J., Schreiber W., Pollmacher T., Holsboer F., Krieg J.C. Sleep in schizophrenia: a polysomnographic study on drug-naive patients. Neuropsychopharmacology 1997, 16(1):51-60.
21. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lassig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382(9896):951-962.
22. Lewis D.A., Cho R.Y., Carter C.S., Eklund K., Forster S., Kelly M.A., Montrose D. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry 2008, 165(12):1585-1593.
23. Manoach D.S., Cain M.S., Vangel M.G., Khurana A., Goff D.C., Stickgold R. A failure of sleep-dependent procedural learning in chronic, medicated schizophrenia. Biol. Psychiatry 2004, 56(12):951-956.
24. McCall W.V., Perlis M.L., Tu X., Groman A.E., Krystal A., Walsh J.K. A comparison of placebo and no-treatment during a hypnotic clinical trial. Int. J. Clin. Pharmacol. Ther. 2005, 43(8):355-359.
25. Misawa F., Shimizu K., Fujii Y., Miyata R., Koshiishi F., Kobayashi M., Shida H., Oguchi Y., Okumura Y., Ito H., Kayama M., Kashima H. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry 2011, 11:118.
26. Monti J.M., Monti D. Sleep disturbance in schizophrenia. Int. Rev. Psychiatry 2005, 17(4):247-253.
27. Morin C.M., Colecchi C., Stone J., Sood R., Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999, 281(11):991-999.
28. Palmese L.B., DeGeorge P.C., Ratliff J.C., Srihari V.H., Wexler B.E., Krystal A.D., Tek C. Insomnia is frequent in schizophrenia and associated with night eating and obesity. Schizophr. Res. 2011, 133(1-3):238-243.
29. Pollack M., Kinrys G., Krystal A., McCall W.V., Roth T., Schaefer K., Rubens R., Roach J., Huang H., Krishnan R. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch. Gen. Psychiatry 2008, 65(5):551-562.
30. Poulin J., Daoust A.M., Forest G., Stip E., Godbout R. Sleep architecture and its clinical correlates in first episode and neuroleptic-naive patients with schizophrenia. Schizophr. Res. 2003, 62(1-2):147-153.
31. Ritsner M., Kurs R., Ponizovsky A., Hadjez J. Perceived quality of life in schizophrenia: relationships to sleep quality. Qual. Life Res. 2004, 13(4):783-791.
32. Roth T., Walsh J.K., Krystal A., Wessel T., Roehrs T.A. An evaluation of the efficacy and safety of eszopiclone over 12months in patients with chronic primary insomnia. Sleep Med. 2005, 6(6):487-495.
33. Sainani K.L. Making sense of intention-to-treat. PM R 2010, 2(3):209-213.
34. Sheffield J.M., Gold J.M., Strauss M.E., Carter C.S., MacDonald A.W., Ragland J.D., Silverstein S.M., Barch D.M. Common and specific cognitive deficits in schizophrenia: relationships to function. Cogn. Affect. Behav. Neurosci. 2014, 14(1):161-174.
35. Shekleton J.A., Rogers N.L., Rajaratnam S.M. Searching for the daytime impairments of primary insomnia. Sleep Med. Rev. 2010, 14(1):47-60.
36. Silva G.E., Goodwin J.L., Sherrill D.L., Arnold J.L., Bootzin R.R., Smith T., Walsleben J.A., Baldwin C.M., Quan S.F. Relationship between reported and measured sleep times: the sleep heart health study (SHHS). J. Clin. Sleep Med. 2007, 3(6):622-630.
37. Uchimura N., Kamijo A., Takase T. Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study. Ann. Gen. Psychiatry 2012, 11(1):15.
38. Walsh J.K., Krystal A.D., Amato D.A., Rubens R., Caron J., Wessel T.C., Schaefer K., Roach J., Wallenstein G., Roth T. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007, 30(8):959-968.
39. Wamsley E.J., Shinn A.K., Tucker M.A., Ono K.E., McKinley S.K., Ely A.V., Goff D.C., Stickgold R., Manoach D.S. The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a randomized placebo-controlled trial. Sleep 2013, 36(9):1369-1376.
40. Winkelman J.W. Schizophrenia, obesity, and obstructive sleep apnea. J. Clin. Psychiatry 2001, 62(1):8-11.
41. Wirshing D.A., Pierre J.M., Wirshing W.C. Sleep apnea associated with antipsychotic-induced obesity. J. Clin. Psychiatry 2002, 63(4):369-370.
42. Ziedonis D.M., Smelson D., Rosenthal R.N., Batki S.L., Green A.I., Henry R.J., Montoya I., Parks J., Weiss R.D. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J. Psychiatr. Pract. 2005, 11(5):315-339.